Skip to content
HowShorted

Syndax Pharmaceuticals Inc short interest in 2021

In 2021, Syndax Pharmaceuticals Inc's disclosed short interest ran from 13.15% of shares outstanding on 15 Jan 2021 to 6.81% on 31 Dec 2021, a change of -6.34 percentage points. The year's high was 17.90% on 15 Jul 2021 and its low 6.43% on 30 Nov 2021, averaging 13.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.90 days on 28 May 2021. Full history: Syndax Pharmaceuticals Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Syndax Pharmaceuticals Inc in 2021

2021 in figures

Start of year
13.15% (15 Jan 2021)
End of year
6.81% (31 Dec 2021)
Change
-6.34 pp
High
17.90% (15 Jul 2021)
Low
6.43% (30 Nov 2021)
Average
13.22%
Highest days to cover
23.90 (28 May 2021)
SEC filings marked
8

Every report in 2021

Syndax Pharmaceuticals Inc short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202113.15%14.05
29 Jan 202111.82%6.68
12 Feb 202112.07%12.71
26 Feb 202112.06%9.33
15 Mar 202111.01%6.46results (8-K), 10-K filed
31 Mar 202114.09%9.13
15 Apr 202113.08%11.93
30 Apr 202115.22%3.86
14 May 202115.04%9.2910-Q filed, results (8-K)
28 May 202115.61%23.90
15 Jun 202116.00%17.07
30 Jun 202116.28%10.45
15 Jul 202117.90%21.04
30 Jul 202116.97%21.71
13 Aug 202116.51%22.5010-Q filed, results (8-K)
31 Aug 202116.96%21.24
15 Sep 202116.08%16.25
30 Sep 202114.32%8.87
15 Oct 202113.01%11.19
29 Oct 202112.89%18.44
15 Nov 20216.89%5.2310-Q filed, results (8-K)
30 Nov 20216.43%7.75
15 Dec 20217.19%4.63
31 Dec 20216.81%4.50

See also: Syndax Pharmaceuticals Inc's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.